The role of DPP4 activity in cardiovascular districts: In vivo and in vitro evidence

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Pala, L ^a   Rotella, C M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; EXENDIN 4; FIBRIN; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROPEPTIDE Y; PARATHYROID HORMONE; STREPTOZOCIN; STROMAL CELL DERIVED FACTOR 1; THROMBOPLASTIN; VASCULOTROPIN; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANTICOAGULATION; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBRIN POLYMERIZATION; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; STREPTOZOCIN DIABETES; THROMBOCYTE AGGREGATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CARDIOVASCULAR SYSTEM; DRUG EFFECT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

ANIMALS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84880112851     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/590456     Document Type: Review

References (29)

1. Mannucci E., Rotella C. M., Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases 2008 18 9 639 645 2-s2.0-54049110924 10.1016/j.numecd.2008.08.002
2. Jose T., Inzucchi S. E., Cardiovascular effects of the DPP-4 inhibitors. Diabetes and Vascular Disease Research 2012 9 2 109 116
3. Mannucci E., Dicembrini I., Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion 2012 28 5 715 721
4. Gejl M., Søndergaard H. M., Stecher C., Bibby B. M., Møller N., Bøtker H. E., Hansen S. B., Gjedde A., Rungby J., Brock B., Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2012 97 E1165 E1169
5. Best J. H., Hoogwerf B. J., Herman W. H., Pelletier E. M., Smith D. B., Wenten M., Hussein M. A., Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the Glucagon-Like Peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. Diabetes Care 2011 34 1 90 95 2-s2.0-79951702236 10.2337/dc10-1393
6. Dicembrini I., Pala L., Rotella C. M., From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Experimental Diabetes Research 2011 2011 8 2-s2.0-80052716020 10.1155/2011/898913 898913
7. Aghili N., Joseph Devaney M., Lee Alderman O., Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis. Neuropeptides 2012 46 367 371
8. Augustyns K., Bal G., Thonus G., Belyaev A., Zhang X. M., Bollaert W., Lambeir A. M., Durinx C., Goossens F., Haemers A., The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Current Medicinal Chemistry 1999 6 4 311 327 2-s2.0-0032961099
9. Drucker D. J., Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007 30 6 1335 1343 2-s2.0-34249902025 10.2337/dc07-0228
10. Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., Cremasco F., Ognibene A., Rotella C. M., Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005 48 6 1168 1172 2-s2.0-21344451403 10.1007/s00125-005-1749-8
11. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D. M., Eckardt K., Kaufman J. M., Ryden M., Müller S., Hanisch F.-G., Ruige J., Arner P., Sell H., Eckel J., Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011 60 7 1917 1925 2-s2.0-80052096595 10.2337/db10-1707
12. Fadini G. P., Avogaro A., Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascular Pharmacology 2011 55 1-3 10 16 2-s2.0-80051795160 10.1016/j.vph.2011.05.001
13. Rizzo M., Rizvi A. A., Spinas G. A., Rini G. B., Berneis K., Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opinion on Investigational Drugs 2009 18 10 1495 1503 2-s2.0-70349319712 10.1517/14728220903241633
14. Zhong J., Rao X., Rajagopalan S., An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013 226 2 305 314
15. Kirino Y., Sei M., Kawazoe K., Minakuchi K., Sato Y., Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocrine Journal 2012 59 10 949 953
16. Kirino Y., Sato Y., Kamimoto T., Kawazoe K., Minakuchi K., Nakahori Y., Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. Journal of Endocrinology 2009 200 1 53 61 2-s2.0-67449155340 10.1677/JOE-08-0424
17. Ku H.-C., Chen W.-P., Su M.-J., DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn-Schmiedeberg's Archives of Pharmacology 2011 384 2 197 207 2-s2.0-79961172510 10.1007/s00210-011-0665-3
18. Sauvé M., Ban K., Abdul Momen M., Zhou Y.-Q., Henkelman R. M., Husain M., Drucker D. J., Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010 59 4 1063 1073 2-s2.0-77951168113 10.2337/db09-0955
19. Segers V. F. M., Revin V., Wu W., Qiu H., Yan Z., Lee R. T., Sandrasagra A., Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation 2011 123 12 1306 1315 2-s2.0-79954630368 10.1161/CIRCULATIONAHA.110.991786
20. Huber B. C., Brunner S., Segeth A., Nathan P., Fischer R., Zaruba M. M., Vallaster M., Theiss H. D., David R., Gerbitz A., Franz W.-M., Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischaemic heart. Cardiovascular Research 2011 90 3 529 537 2-s2.0-79957455928 10.1093/cvr/cvr014
21. Shigeta T., Aoyama M., Bando Y. K., Monji A., Mitsui T., Takatsu M., Cheng X. W., Okumura T., Hirashiki A., Nagata K., Murohara T., Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012 126 15 1838 1851
22. Gomez N., Matheeussen V., Damoiseaux C., Tamborini A., Merveille A. C., Jespers P., Michaux C., Clercx C., De Meester I., McEntee K., Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs. Journal of Veterinary Internal Medicine 2012 26 4 929 934
23. Pala L., Pezzatini A., Dicembrini I., Ciani S., Gelmini S., Vannelli B. G., Cresci B., Mannucci E., Rotella C. M., Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetologica 2012 49, supplement 1 S59 S63 2-s2.0-77951876419 10.1007/s00592-010-0195-3
24. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., Hayashi T., A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010 53 10 2256 2263 2-s2.0-77958052010 10.1007/s00125-010- 1831-8
25. Xie X.-Y., Mo Z.-H., Chen K., He H.-H., Xie Y.-H., Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Medical Science Monitor 2011 17 2 BR35 BR41 2-s2.0-79551706382
26. Lee E. W., Michalkiewicz M., Kitlinska J., Kalezic I., Switalska H., Yoo P., Sangkharat A., Ji H., Li L., Michalkiewicz T., Ljubisavljevic M., Johansson H., Grant D. S., Zukowska Z., Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. Journal of Clinical Investigation 2003 111 12 1853 1862 2-s2.0-0043245868 10.1172/JCI200316929
27. Bušek P., Stremeňová J., Křepela E., Šedo A., Modulation of substance P signaling by dipeptidyl peptidase-IV enzymatic activity in human glioma cell lines. Physiological Research 2008 57 443 449
28. Mentlein R., Heymann E., Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers. Archives of Biochemistry and Biophysics 1982 217 2 748 750 2-s2.0-0020364739
29. Krijnen P. A. J., Hahn N. E., Kholová I., Baylan U., Sipkens J. A., Van Alphen F. P., Vonk A. B. A., Simsek S., Meischl C., Schalkwijk C. G., Van Buul J. D., Van Hinsbergh V. W. M., Niessen H. W. M., Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Research in Cardiology 2012 107 1, article 233 2-s2.0-84856971572 10.1007/s00395-011- 0233-5